Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

MrPeanutEsquire Jun. 10 at 1:26 PM

$PFE Theres a rumor going around that I might raise my target price for PFE. Make sure you get in before that happens!

0 · Reply

MrPeanutEsquire Jun. 10 at 1:23 PM

$PFE Pfun fact of the day. We are the 35th cheapest stock in the entire s&p on a forward pe basis.

0 · Reply

Mike22332233 Jun. 10 at 11:04 AM

$VNDA The Home Run for the $VNDA BO may very well be Tradipiant for GLP-1 nausea …. $PFE & $LLY have a great need for this drug ALONG with BYSANTI … The SUPER-HUGE market for tradipitant will be the $15 BILLION GLP-1 nausea market today, which is projected at GROWING to $45-$60 BILLION by 2030!!! That is why a GL-1 Pharma will do a buyout soon !! ….. It will end up being a blockbuster drug against GLP-1 nausea … top-line results from a Phase II study indicated that Vandas’ tradipitant was effective at reducing vomiting and nausea caused by GLP-1 receptor agonists like Wegovy in adults … FOLLOW me 👉 @Mike22332233 for latest info AND, nobody is thinking of this .... ALMOST ALL Cancer Chemo/Drugs have some amount of nausea associated with them .... AND HOLD STEADY as I tell you the market size here .... In 2025, worldwide spending on oncology medicines (at list prices) reached $252 billion and is projected to potentially reach nearly $700 billion by 2034 ....

0 · Reply

ap12345 Jun. 10 at 1:34 AM

$PFE anyone have a RH that got early dividend? I got it at .40 but shouldnt it have been .43?

1 · Reply

MarcoFla99 Jun. 10 at 12:55 AM

$PFE I keep buying. So damn cheap with agreat divy. CEO still sucks imo but he should buy Sellas (SLS) before someone else does. JMHO

0 · Reply

Willieberich Jun. 9 at 11:39 PM

$PFE you guys are not connected to reality if you see this going down anytime soon past 25.17 ! The back test to 28and change is done .. we are being lied too 100 percent with data . Mary is stealing from John is stealing from Mary. It's a circle jerk for your new ipo space jerks and the other hopiums..coming up .open my ass .com ..I'll stick with reality of the economy with the people that are having a hard time paying for food .while all the billionaires become trillionairs.the rel facts are your not them .chase your dreams in a casino. I know what's wroth my money .this company is 1 of those .stop listening to talking heads in twits .they are not your friends. Good luck people..

0 · Reply

flychicken1991 Jun. 9 at 11:06 PM

$PFE Conclusion: likely positive because FDA expanded HYMPAVZI to hemophilia A/B patients 12+ with inhibitors and children 6-11 with or without inhibitors. AI impact thesis: not AI; this is label expansion. Mechanism: broader U.S. indication can lift addressable market and once-weekly subcutaneous prophylaxis uptake. Risk/Watch: patient pool size, payer access, launch uptake, and safety scrutiny. https://clawpool.hihired.org/newsimpact/?ticker=PFE&utm_source=stocktwits&utm_medium=parent_url Not financial advice.

0 · Reply

LordEnglandRebirth Jun. 9 at 7:47 PM

$PFE $25.60

0 · Reply

Micheal_Pothead Jun. 9 at 7:40 PM

$PFE Albert for the love of God buy some shares, it’s not a good look when the CEO never buys any shares

0 · Reply

Micheal_Pothead Jun. 9 at 7:21 PM

$PFE weak close incoming

2 · Reply

Pfizer CEO warns German investment at risk over drug pricing policies

2026-06-09T21:05:52.000Z - 16 hours ago

Pfizer upgraded to Sector Perform from Underperform at RBC Capital

2026-06-09T21:05:12.000Z - 16 hours ago

Pfizer upgraded to Sector Perform at RBC Capital amid more balanced risk-reward

Jun 9, 2026, 2:07 PM EDT - 19 hours ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Jun 9, 2026, 9:20 AM EDT - 1 day ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

Jun 9, 2026, 3:20 AM EDT - 1 day ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Jun 8, 2026, 8:00 AM EDT - 2 days ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T10:51:57.000Z - 2 days ago

Pfizer says FDA approves expanded indication for Hympavzi

Jun 8, 2026, 6:49 AM EDT - 2 days ago

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:45 AM EDT - 2 days ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

2026-06-07T22:00:49.000Z - 2 days ago

Pfizer presents results from Phase 2b studies of berobenatide

Jun 6, 2026, 11:00 AM EDT - 3 days ago

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 3 days ago

Pfizer Slides: Study update

Jun 6, 2026, 9:06 AM EDT - 4 days ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:00 AM EDT - 4 days ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 4, 2026, 10:00 AM EDT - 5 days ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 6:40 AM EDT - 6 days ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Jun 3, 2026, 2:00 PM EDT - 6 days ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 10:00 AM EDT - 8 days ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

2026-05-31T13:45:07.000Z - 9 days ago

Pfizer announces results from Cohort 3 on Bratovi with cetuximab, Folfiri

2026-05-31T13:25:52.000Z - 10 days ago

Pfizer announces results from Phase 3 Talapro-3 study of Talzenna, Xtandi

May 31, 2026, 8:00 AM EDT - 10 days ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 30, 2026, 9:22 AM EDT - 11 days ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA

May 30, 2026, 8:00 AM EDT - 11 days ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

2026-05-29T13:17:15.000Z - 12 days ago

Pfizer announces seven-year follow-up results from Phase 3 CROWN trial

May 29, 2026, 8:00 AM EDT - 12 days ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 28, 2026, 11:10 PM EDT - 12 days ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 7:19 PM EDT - 12 days ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

2026-05-28T23:05:16.000Z - 12 days ago

Pfizer enters into global strategic collaboration with Innovent Biologics

May 28, 2026, 7:00 PM EDT - 12 days ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 12 days ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

2026-05-28T12:35:12.000Z - 13 days ago

Guardant Health to present 38 abstracts at ASCO 2026 meeting

May 27, 2026, 10:00 AM EDT - 13 days ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 20, 2026, 9:00 AM EDT - 21 days ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

2026-05-20T09:30:10.000Z - 21 days ago

Pfizer announces pneumococcal conjugate vaccine candidate data

May 20, 2026, 5:08 AM EDT - 21 days ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:05 AM EDT - 21 days ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

2026-05-18T17:01:06.000Z - 22 days ago

PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’

AZN LLY NVO SNY

May 18, 2026, 8:00 AM EDT - 23 days ago

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 14, 2026, 2:22 PM EDT - 26 days ago

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

DGX MO CL

May 13, 2026, 6:45 AM EDT - 4 weeks ago

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

May 12, 2026, 8:00 AM EDT - 4 weeks ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

ARVN RIGL

May 12, 2026, 7:00 AM EDT - 4 weeks ago

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

ARVN

May 5, 2026, 4:09 PM EDT - 5 weeks ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:02 PM EDT - 5 weeks ago

Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 11:30 AM EDT - 5 weeks ago

3 Dividend Stocks for May 2026

SYY WSO

May 5, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Slides: Q1 2026

May 5, 2026, 8:35 AM EDT - 5 weeks ago

Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 7:23 AM EDT - 5 weeks ago

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

May 5, 2026, 7:06 AM EDT - 5 weeks ago

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

May 5, 2026, 7:05 AM EDT - 5 weeks ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS

May 5, 2026, 6:55 AM EDT - 5 weeks ago

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

May 5, 2026, 6:51 AM EDT - 5 weeks ago

Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis

May 5, 2026, 6:45 AM EDT - 5 weeks ago

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

May 1, 2026, 12:37 PM EDT - 5 weeks ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN

Apr 29, 2026, 7:42 AM EDT - 6 weeks ago

Pfizer's blood cancer drug meets main goal in late-stage trial

$Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma$

Apr 29, 2026, 6:45 AM EDT - 6 weeks ago

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Apr 28, 2026, 10:41 AM EDT - 6 weeks ago

Pfizer secures deals to keep heart drug free of generic rivals until 2031

Apr 28, 2026, 10:17 AM EDT - 6 weeks ago

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Apr 24, 2026, 8:36 AM EDT - 6 weeks ago

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

BMY

Apr 23, 2026, 9:00 AM EDT - 6 weeks ago

Pfizer Transcript: AGM 2026

Apr 22, 2026, 4:45 PM EDT - 6 weeks ago

Pfizer Declares Second-Quarter 2026 Dividend

Apr 22, 2026, 5:18 AM EDT - 7 weeks ago

Pfizer GLP-1 weight loss drug available for pre-order in China

Apr 21, 2026, 11:51 AM EDT - 7 weeks ago

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Apr 20, 2026, 3:05 PM EDT - 7 weeks ago

Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says

Apr 20, 2026, 6:45 AM EDT - 7 weeks ago

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Apr 16, 2026, 1:01 PM EDT - 7 weeks ago

The Big 3: PFE, V, SYF

SYF V

MrPeanutEsquire Jun. 10 at 1:26 PM

$PFE Theres a rumor going around that I might raise my target price for PFE. Make sure you get in before that happens!

0 · Reply

MrPeanutEsquire Jun. 10 at 1:23 PM

$PFE Pfun fact of the day. We are the 35th cheapest stock in the entire s&p on a forward pe basis.

0 · Reply

Mike22332233 Jun. 10 at 11:04 AM

0 · Reply

ap12345 Jun. 10 at 1:34 AM

$PFE anyone have a RH that got early dividend? I got it at .40 but shouldnt it have been .43?

1 · Reply

MarcoFla99 Jun. 10 at 12:55 AM

$PFE I keep buying. So damn cheap with agreat divy. CEO still sucks imo but he should buy Sellas (SLS) before someone else does. JMHO

0 · Reply

Willieberich Jun. 9 at 11:39 PM

0 · Reply

flychicken1991 Jun. 9 at 11:06 PM

0 · Reply

LordEnglandRebirth Jun. 9 at 7:47 PM

$PFE $25.60

0 · Reply

Micheal_Pothead Jun. 9 at 7:40 PM

$PFE Albert for the love of God buy some shares, it’s not a good look when the CEO never buys any shares

0 · Reply

Micheal_Pothead Jun. 9 at 7:21 PM

$PFE weak close incoming

2 · Reply

TheUnmaker Jun. 9 at 6:20 PM

$TNXP $LLY $JNJ $PFE $PG Dip buyers know a good dip!

0 · Reply

TheUnmaker Jun. 9 at 6:17 PM

$TNXP $PFE $QSI The dip before the rip. The dips getting bought up!

0 · Reply

JBS_84 Jun. 9 at 5:17 PM

$PFE Just retesting 25.73. hope it holds. Then we can go reject 26.2 again

1 · Reply

Micheal_Pothead Jun. 9 at 5:14 PM

$PFE time to pfade

0 · Reply

STOCKPICKERTRADER Jun. 9 at 4:57 PM

$PFE clearly demonstrating the pursuit of undervalued income generating opportunities as investors rotate out of the parabolic movements in anything AI regardless of fundamentals.

0 · Reply

nimii Jun. 9 at 4:24 PM

$PFE go ahead make my day 💰

0 · Reply

STOCKPICKERTRADER Jun. 9 at 4:12 PM

$PFE enjoy that +6.71% yield while shares grind into the 30's for a nice growth and income option here and few others $KMB $NVO

0 · Reply

STOCKPICKERTRADER Jun. 9 at 4:02 PM

$PFE markets going to force the rotation into more value plays and this is certainly one of them with shoe into that income generating value play!

1 · Reply

edlu77 Jun. 9 at 3:55 PM

$PFE Don’t worry guys. We might be red when the market goes up, but we make up for it by being slightly less red when the market goes down

2 · Reply

Micheal_Pothead Jun. 9 at 3:42 PM

$PFE literally not allowed to be green

0 · Reply

MrPeanutEsquire Jun. 9 at 3:40 PM

$PFE At least we will have cheap shares for our dividend I guess. So thats good I guess.... horay

3 · Reply

dust6431 Jun. 9 at 3:12 PM

$PFE What exactly has he done?

3 · Reply

Market Cap	146.02B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	8.51
Forward PE	8.72
Profit Margin	12.42%
Debt to Equity Ratio	0.71

Volume	35,273,200
Avg Vol	35,295,664
Day's Range	N/A - N/A
Shares Out	5.70B
Stochastic %K	43%
Beta	0.34
Analysts	Sell
Price Target	$29.28